| Vorliegende Sprache |
eng |
| Hinweise auf parallele Ausgaben |
323696775 Buchausg. u.d.T.: ‡Bogdan, Boris: Valuation in life sciences |
| ISBN |
978-3-642-10819-8 |
| Name |
Bogdan, Boris |
| Villiger, Ralph |
| Name ANZEIGE DER KETTE |
Villiger, Ralph |
| T I T E L |
Valuation in Life Sciences |
| Zusatz zum Titel |
A Practical Guide |
| Verlagsort |
Berlin, Heidelberg |
| Verlag |
Springer Berlin Heidelberg |
| Erscheinungsjahr |
2010 |
| 2010 |
| Umfang |
Online-Ressource (XI, 370p. 158 illus, digital) |
| Reihe |
SpringerLink. Bücher |
| Notiz / Fußnoten |
LIteraturverz. S. 363 - 364 |
| Weiterer Inhalt |
CONTENTS; Introduction; The Life Sciences Industry; Academia; Biotech; Pharma; Valuation; The Role of Valuation; Current Problems in Valuation; Basics of Valuation; Introduction; Fundamentals; Cash Flows; Discounting; Valuation Methods; Discounted Cash Flows Valuation; Decision Tree; Real Options; Difference Between Real Options and Financial Options; Valuation of Financial Options; Valuation in Life Sciences; Fundamentals; Drug Development; Medical Device Development and Approval; Cost; Success Rates; Time; Peak Sales; Discounting; Volatility; Project Valuation; Project Valuation: DCF. Project Valuation: Decision TreeProject Valuation: Real Options; Simulations of Projects; Sensitivity Analysis and Sensitivity-Simulations; License Contract Valuation; Fundamentals of Licensing; Valuation of License Contracts: DCF; Valuation of License Contracts: Real Options; Advanced Topics in Project and License Contract Valuation; Early-Stage Licensing with Possible Sublicensing; Simulation of License Contracts; Discovery and Preclinical License Deals: What's Realistic?; How to Read a Deal; The Virtual Company Model; Negotiating License Deals. Valuing License Contracts with Multiple IndicationsValuing Projects with Multiple Markets; Technology Valuation and Feed Rate; IP Valuation; Pipeline Valuation; Portfolio Management; Introduction; Qualitative Approaches; Quantitative Approaches; Optimal Portfolio Structure; Company and Stock Valuation; Introduction to Company Valuation; Theory; Interpretation of Valuation Results; Simulation on Company Level; Case Company Valuation; Stock Valuation; Advanced Company Valuation; Mergers and Acquisitions; Other, Less Serious Approaches; Exercises; Introduction; Exercises; Solutions; Case Studies. IntroductionCase Study 1; Case Study 2; Case Study 3; Case Study 4; References; Index |
| Titelhinweis |
Buchausg. u.d.T.: ‡Bogdan, Boris: Valuation in life sciences |
| ISBN |
ISBN 978-3-642-10820-4 |
| Klassifikation |
KFFK |
| BUS004000 |
| KFF |
| BUS027000 |
| 657.8333 |
| 658.152 |
| 615.190681 |
| 332 |
| 338.436151 |
| HG1-9999 |
| HG4501-6051 |
| HG1501-HG3550 |
| QW 300 |
| Kurzbeschreibung |
Introduction -- The Life Sciences Industry -- Valuation -- Project Valuation -- License Contract Valuation -- Technology Valuation -- IP Valuation -- Firm Valuation -- Advanced Topics -- Valuation and Gut Feeling -- Excercises |
| 2. Kurzbeschreibung |
This book is the first complete guide to valuation in life sciences for industry professionals, investors, and academics. Boris Bogdan and Ralph Villiger introduce the characteristics of drug and medical device development, explain how to translate these into the valuation, and provide valuable industry data. After guiding the reader through the theory of valuation, including DCF, decision trees, and real options, the authors demonstrate how to value projects, patents, licences, firms, and stocks on real-life examples, even treating complex licence and company structures. Special emphasis is put on the practicability of the proposed methods by including many hands-on examples, without compromising on realistic results. The 3rd edition of the successful work includes new studies about success rates and about drug development in the biotech industry and their influence on valuation |
| 1. Schlagwortkette |
Pharmazeutische Industrie |
| Biotechnologie |
| Kapitalbeschaffung |
| Unternehmensbewertung |
| Risikokapital |
| Realoption |
| 1. Schlagwortkette ANZEIGE DER KETTE |
Pharmazeutische Industrie -- Biotechnologie -- Kapitalbeschaffung -- Unternehmensbewertung -- Risikokapital -- Realoption |
| 2. Schlagwortkette |
Pharmazeutische Industrie |
| Biotechnologie |
| Kapitalbeschaffung |
| Unternehmensbewertung |
| Risikokapital |
| Realoption |
| ANZEIGE DER KETTE |
Pharmazeutische Industrie -- Biotechnologie -- Kapitalbeschaffung -- Unternehmensbewertung -- Risikokapital -- Realoption |
| SWB-Titel-Idn |
323614701 |
| Signatur |
Springer E-Book |
| Bemerkungen |
Elektronischer Volltext - Campuslizenz |
| Elektronische Adresse |
$uhttp://dx.doi.org/10.1007/978-3-642-10820-4 |
| Internetseite / Link |
Volltext |
| Siehe auch |
Inhaltsverzeichnis |
| Siehe auch |
Inhaltstext |
| Siehe auch |
Volltext |
| Siehe auch |
Cover |
